Amgen Inc. $AMGN Stock Bought by ProShare Advisors LLC

ProShare Advisors LLC increased its holdings in Amgen Inc. (NASDAQ:AMGN) by 2.3% in the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 713,097 shares of the medical research company’s stock after buying an additional 16,067 shares during the period. Amgen comprises approximately 0.4% of ProShare Advisors LLC’s investment portfolio, making the stock its 28th biggest holding. ProShare Advisors LLC owned about 0.13% of Amgen worth $300,578,000 as of its most recent SEC filing.

Several other hedge funds also recently added to or reduced their stakes in the business. Rational Advisors Inc. increased its stake in Amgen by 13.7% during the 2nd quarter. Rational Advisors Inc. now owns 199 shares of the medical research company’s stock worth $72,000 after buying an additional 24 shares in the last quarter. Beacon Financial Advisory LLC raised its holdings in Amgen by 2.0% during the second quarter. Beacon Financial Advisory LLC now owns 1,274 shares of the medical research company’s stock worth $461,000 after purchasing an additional 25 shares in the last quarter. James T. Borello RIA grew its holdings in shares of Amgen by 13.6% during the 3rd quarter. James T. Borello RIA now owns 209 shares of the medical research company’s stock worth $88,000 after purchasing an additional 25 shares during the period. Sweeney & Michel LLC increased its position in shares of Amgen by 0.5% during the third quarter. Sweeney & Michel LLC now owns 5,129 shares of the medical research company’s stock worth $2,162,000 after acquiring an additional 25 shares during the last quarter. Finally, Legacy Financial Advisors Inc. lifted its position in shares of Amgen by 0.8% in the 2nd quarter. Legacy Financial Advisors Inc. now owns 3,407 shares of the medical research company’s stock worth $1,234,000 after buying an additional 26 shares during the last quarter. 76.50% of the stock is owned by hedge funds and other institutional investors.

Amgen Stock Performance

Shares of NASDAQ:AMGN opened at $466.01 on Friday. The company has a debt-to-equity ratio of 4.44, a current ratio of 1.37 and a quick ratio of 1.13. The business’s 50 day moving average price is $419.96 and its 200-day moving average price is $374.79. Amgen Inc. has a 1 year low of $288.00 and a 1 year high of $475.65. The firm has a market capitalization of $251.94 billion, a PE ratio of 28.96, a P/E/G ratio of 3.41 and a beta of 0.41.

Amgen (NASDAQ:AMGN) last posted its quarterly earnings data on Tuesday, August 4th. The medical research company reported $6.29 earnings per share for the quarter, beating the consensus estimate of $5.62 by $0.67. Amgen had a return on equity of 124.14% and a net margin of 22.95%. The business had revenue of $10.05 billion during the quarter, compared to the consensus estimate of $9.43 billion. During the same period in the prior year, the company earned $6.02 earnings per share. The company’s revenue was up 9.5% compared to the same quarter last year. Amgen has set its FY 2026 guidance at 22.300-23.500 EPS. As a group, equities research analysts expect that Amgen Inc. will post 22.96 earnings per share for the current fiscal year.

Amgen Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, December 11th. Stockholders of record on Friday, November 20th will be issued a dividend of $2.52 per share. The ex-dividend date is Friday, November 20th. This represents a $10.08 dividend on an annualized basis and a dividend yield of 2.2%. Amgen’s dividend payout ratio (DPR) is currently 62.65%.

Trending Headlines about Amgen

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Dividend support: Amgen’s dividend announcement helped reinforce the stock’s income appeal and contributed to its move to a new 1-year high. Amgen Sets New 1-Year High Following Dividend Announcement
• Positive Sentiment: Analyst endorsement: RBC Capital reaffirmed its Buy rating, providing continued Wall Street support ahead of the earnings release. RBC Capital Reaffirms Buy Rating
• Positive Sentiment: Pipeline and rare-disease progress: New Phase 3 dazodalibep data in Sjögren’s disease, UPLIZNA updates and a rare-disease diagnostic collaboration support Amgen’s longer-term growth narrative beyond its established products. Rare Disease Updates
• Neutral Sentiment: Key near-term catalyst: Amgen will report third-quarter 2026 results after the market close on November 3. The current consensus EPS estimate cited in previews is $5.79, making earnings, guidance and management commentary important tests for the recent rally. Amgen Q3 2026 Preview
• Negative Sentiment: Profitability concerns: Management has warned of rising expenses, while MariTide development is consuming substantial cash. Investors are watching whether growth from Repatha and TEZSPIRE can offset higher costs and protect margins. Amgen Faces Rising Expenses Ahead of Q3 Results
• Negative Sentiment: Valuation and execution risk: A skeptical earnings preview highlights concerns about the CFO transition, spending growth and whether Amgen can meet expectations after a substantial year-to-date advance. Amgen Earnings Preview

Analysts Set New Price Targets

A number of equities analysts have recently weighed in on AMGN shares. Mizuho upped their target price on Amgen from $303.00 to $352.00 and gave the company a “neutral” rating in a report on Tuesday, August 18th. Jefferies Financial Group reaffirmed a “hold” rating and set a $410.00 target price on shares of Amgen in a report on Wednesday, September 23rd. Morgan Stanley cut their price target on Amgen from $362.00 to $359.00 and set an “equal weight” rating on the stock in a research note on Wednesday, October 7th. Robert W. Baird lifted their target price on Amgen from $215.00 to $230.00 and gave the company an “underperform” rating in a research report on Wednesday, August 5th. Finally, UBS Group raised their target price on shares of Amgen from $430.00 to $470.00 and gave the company a “buy” rating in a research note on Friday, October 9th. One investment analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, sixteen have given a Hold rating and three have assigned a Sell rating to the company. According to MarketBeat, Amgen has an average rating of “Hold” and an average price target of $389.71.

Insider Buying and Selling

In other news, SVP Nancy Grygiel sold 2,970 shares of the firm’s stock in a transaction dated Thursday, August 6th. The shares were sold at an average price of $402.16, for a total transaction of $1,194,415.20. Following the completion of the transaction, the senior vice president directly owned 7,340 shares of the company’s stock, valued at approximately $2,951,854.40. This trade represents a 28.81% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, SVP Rachna Khosla sold 1,252 shares of the firm’s stock in a transaction dated Thursday, August 13th. The stock was sold at an average price of $416.43, for a total value of $521,370.36. Following the sale, the senior vice president directly owned 6,404 shares in the company, valued at approximately $2,666,817.72. This represents a 16.35% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 6,222 shares of company stock worth $2,540,926 in the last ninety days. Insiders own 0.85% of the company’s stock.

Amgen Profile

Amgen Inc is a biotechnology company that discovers, develops, manufactures and delivers medicines for serious illnesses. Its research focuses on areas including oncology, cardiovascular disease, inflammation, bone health, nephrology and neuroscience.

The company’s products include biologic and specialty medicines such as Enbrel for inflammatory diseases, Prolia and Evenity for osteoporosis, Xgeva for skeletal-related complications, Repatha for cardiovascular risk reduction, Otezla for inflammatory conditions, Tezspire for severe asthma, Blincyto for certain blood cancers, and Lumakras for specific cancers.

Founded in 1980, Amgen is headquartered in Thousand Oaks, California.